Ritchlin, Christopher T. http://orcid.org/0000-0002-2602-1219
Mease, Philip J. http://orcid.org/0000-0002-6620-0457
Boehncke, Wolf-Henning http://orcid.org/0000-0002-1225-7124
Tesser, John http://orcid.org/0000-0002-2706-7171
Chakravarty, Soumya D. http://orcid.org/0000-0001-7957-838X
Rampakakis, Emmanouil http://orcid.org/0000-0002-7427-8246
Shawi, May http://orcid.org/0000-0001-6005-3938
Schiopu, Elena http://orcid.org/0000-0002-1831-5292
Merola, Joseph F. http://orcid.org/0000-0001-6514-4353
McInnes, Iain B. http://orcid.org/0000-0002-6462-4280
Deodhar, Atul http://orcid.org/0000-0002-2130-1246
Funding for this research was provided by:
Janssen Research and Development
Article History
Received: 19 January 2024
Revised: 30 April 2024
Accepted: 2 May 2024
First Online: 7 June 2024
Declarations
:
: <b>CTR:</b> Received grant/research support from AbbVie, Amgen, UCB and consulting fees from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB. <b>PJM:</b> Received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, SUN, and UCB; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Novartis, Pfizer, SUN, UCB, and Ventyx; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. <b>WHB:</b> Received honoraria as a speaker and advisor from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Leo Pharma, Novartis, and UCB. <b>JT:</b> Has served on advisory boards/as a consultant for: AbbVie, Amgen, AstraZeneca, Aurinia, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Samumed/ Biosplice, Sanofi-Genzyme, UCB; served on speaker bureaus for: AbbVie, Amgen, AstraZeneca, Aurinia, Bristol Myers Squibb (through 2021), Eli Lilly, GlaxoSmithKline, Janssen, Pfizer, Sanofi/Genzyme; received research grants and support from: AbbVie, Alpine, Amgen, Anthrosi, Bendcare, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas, CSL Behring, DRL, Eli Lilly, Emerald, Exagen, Genentech, Gilead, Global Health Living Foundation, Horizon, Janssen, Kolon TissueGene, Mitsubishi, Organogenesis, Pfizer, Samumed/Biosplice, Selecta, Setpoint, Sun, Takeda, and Vorso. <b>SDC:</b> Employee of Janssen Scientific Affairs, LLC, and owns stock in Johnson & Johnson. <b>ER:</b> Employee of JSS Medical Research; paid consultant of Janssen. <b>MS:</b> Employee of Janssen Research & Development, LLC, and owns stock in Johnson & Johnson. <b>ES: </b>Received consulting fees and research grants from Janssen <b>JFM:</b> Received consulting fees and investigator honoraria from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Janssen, Leo, Novartis, Pfizer, Regeneron, Sanofi, Sun, and UCB. Current affiliation: Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, USA. <b>IBM:</b> Received consulting fees from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; grant/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo Smith Kline, Janssen, Novartis, Roche, and UCB; is a shareholder for Causeway, and Evelo Compugen; NHS GGC Board Member; Evelo Board of Directors; and Versus Arthritis Trustee. <b>AD:</b> Received consulting fees for participation in advisory boards from Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; research grant funding from Eli Lilly, Novartis, Pfizer, and UCB; and speaker fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB.
: Janssen Research & Development, LLC had a role in the study design and in the collection, analysis, and interpretation of the data, the writing of the manuscript, and the decision to submit the manuscript for publication. Publication of this article was contingent upon approval by Janssen Research & Development, LLC.